{
    "key_points": [
        "The FDA has authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine for children aged 5 through 11.",
        "The vaccine's effectiveness was found to be 90.7% in preventing COVID-19 in the age group.",
        "Safety was studied in approximately 3,100 children age 5 through 11 with no serious side effects detected.",
        "The CDC’s Advisory Committee on Immunization Practices will discuss further recommendations next week.",
        "The vaccine for this age group is administered as a two-dose series with a lower dose than that for ages 12 and up.",
        "COVID-19 cases in children 5 through 11 make up 39% of cases in those younger than 18 in the U.S.",
        "Peter Marks and Janet Woodcock emphasized the rigorous evaluation and transparency of the authorization process.",
        "A new vaccine formulation using Tris buffer has been authorized to improve stability and storage conditions.",
        "Pfizer Inc. has updated its safety monitoring plan to include evaluations of myocarditis and pericarditis among other safety measures.",
        "The FDA and CDC have systems in place for continual safety monitoring of the COVID-19 vaccine."
    ],
    "spokespersons": [
        "Janet Woodcock, M.D. (Acting FDA Commissioner)",
        "Peter Marks, M.D., Ph.D. (Director of the FDA’s Center for Biologics Evaluation and Research)"
    ],
    "article_type": "press release",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}